The group I metabotropic glutamate receptor 5 (mGluR5) has been implicated in the pathology of various neurological disorders including schizophrenia, ADHD, and autism. mGluR5-dependent synaptic plasticity has been described at a variety of neural connections and its signaling has been implicated in several behaviors. These behaviors include locomotor reactivity to novel environment, sensorimotor gating, anxiety, and cognition. mGluR5 is expressed in glutamatergic neurons, inhibitory neurons, and glia in various brain regions. In this study, we show that deleting mGluR5 expression only in principal cortical neurons leads to defective cannabinoid receptor 1 (CB1R) dependent synaptic plasticity in the prefrontal cortex. These cortical glutamatergic mGluR5 knockout mice exhibit increased novelty-induced locomotion, and their locomotion can be further enhanced by treatment with the psychostimulant methylphenidate. Despite a modest reduction in repetitive behaviors, cortical glutamatergic mGluR5 knockout mice are normal in sensorimotor gating, anxiety, motor balance/learning and fear conditioning behaviors. These results show that mGluR5 signaling in cortical glutamatergic neurons is required for precisely modulating locomotor reactivity to a novel environment but not for sensorimotor gating, anxiety, motor coordination, several forms of learning or social interactions.
References
[1]
Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205–237.
[2]
Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50: 295–322.
[3]
Rouach N, Nicoll RA (2003) Endocannabinoids contribute to short-term but not long-term mGluR-induced depression in the hippocampus. Eur J Neurosci 18: 1017–1020.
[4]
Kettunen P, Kyriakatos A, Hallen K, El Manira A (2005) Neuromodulation via conditional release of endocannabinoids in the spinal locomotor network. Neuron 45: 95–104.
[5]
Kreitzer AC, Malenka RC (2005) Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. J Neurosci 25: 10537–10545.
[6]
Safo PK, Regehr WG (2005) Endocannabinoids control the induction of cerebellar LTD. Neuron 48: 647–659.
[7]
Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89: 309–380.
[8]
Regehr WG, Carey MR, Best AR (2009) Activity-dependent regulation of synapses by retrograde messengers. Neuron 63: 154–170.
[9]
Luscher C, Huber KM (2010) Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease. Neuron 65: 445–459.
[10]
She WC, Quairiaux C, Albright MJ, Wang YC, Sanchez DE, et al. (2009) Roles of mGluR5 in synaptic function and plasticity of the mouse thalamocortical pathway. Eur J Neurosci 29: 1379–1396.
[11]
Campanac E, Gasselin C, Baude A, Rama S, Ankri N, et al. (2013) Enhanced intrinsic excitability in basket cells maintains excitatory-inhibitory balance in hippocampal circuits. Neuron 77: 712–722.
[12]
Chevaleyre V, Castillo PE (2003) Heterosynaptic LTD of hippocampal GABAergic synapses: a novel role of endocannabinoids in regulating excitability. Neuron 38: 461–472.
[13]
Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. Trends Neurosci 27: 370–377.
[14]
Dolen G, Bear MF (2008) Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome. J Physiol 586: 1503–1508.
[15]
Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, et al. (2007) Correction of Fragile X Syndrome in Mice. Neuron 56: 955–962.
[16]
Krueger DD, Bear MF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu Rev Med 62: 411–429.
[17]
Bhakar AL, Dolen G, Bear MF (2012) The pathophysiology of fragile X (and what it teaches us about synapses). Annu Rev Neurosci 35: 417–443.
[18]
Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, et al. (2011) Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3: 64ra61.
[19]
Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, et al. (2012) De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. Mol Psychiatry 17: 142–153.
[20]
Elia J, Sackett J, Turner T, Schardt M, Tang SC, et al. (2012) Attention-deficit/hyperactivity disorder genomics: update for clinicians. Curr Psychiatry Rep 14: 579–589.
[21]
Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, et al. (2012) De novo gene disruptions in children on the autistic spectrum. Neuron 74: 285–299.
[22]
Kelleher RJ, 3rd, Geigenmuller U, Hovhannisyan H, Trautman E, Pinard R, et al (2012) High-throughput sequencing of mGluR signaling pathway genes reveals enrichment of rare variants in autism. PLoS ONE 7: e35003.
[23]
Matosin N, Newell KA (2012) Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia. Neurosci Biobehav Rev 37: 256–268.
[24]
Catania MV, D'Antoni S, Bonaccorso CM, Aronica E, Bear MF, et al. (2007) Group I metabotropic glutamate receptors: a role in neurodevelopmental disorders? Mol Neurobiol 35: 298–307.
[25]
Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, et al. (2005) The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl) 179: 218–229.
[26]
Balschun D, Zuschratter W, Wetzel W (2006) Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 142: 691–702.
[27]
Barker GR, Bashir ZI, Brown MW, Warburton EC (2006) A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. Learn Mem 13: 178–186.
[28]
Bordi F, Marcon C, Chiamulera C, Reggiani A (1996) Effects of the metabotropic glutamate receptor antagonist MCPG on spatial and context-specific learning. Neuropharmacology 35: 1557–1565.
[29]
Pietraszek M, Sukhanov I, Maciejak P, Szyndler J, Gravius A, et al. (2005) Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur J Pharmacol 514: 25–34.
[30]
Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, et al. (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306: 116–123.
[31]
Brody SA, Dulawa SC, Conquet F, Geyer MA (2004) Assessment of a prepulse inhibition deficit in a mutant mouse lacking mGlu5 receptors. Mol Psychiatry 9: 35–41.
[32]
Conn PJ, Lindsley CW, Jones CK (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30: 25–31.
[33]
Gray L, van den Buuse M, Scarr E, Dean B, Hannan AJ (2009) Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 12: 45–60.
[34]
Bird MK, Reid CA, Chen F, Tan HO, Petrou S, et al. (2010) Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice. Int J Neuropsychopharmacol 13: 133–141.
Lu YM, Jia Z, Janus C, Henderson JT, Gerlai R, et al. (1997) Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci 17: 5196–5205.
[37]
Kachroo A, Orlando LR, Grandy DK, Chen JF, Young AB, et al. (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25: 10414–10419.
[38]
Palucha A, Pilc A (2007) Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 115: 116–147.
[39]
Witkin JM, Marek GJ, Johnson BG, Schoepp DD (2007) Metabotropic glutamate receptors in the control of mood disorders. CNS Neurol Disord Drug Targets 6: 87–100.
[40]
Shigemoto R, Mizuno N (2000) Metabotropic glutamate receptors - immunocytochemical and in situ hybridization analyses. In: Storm-Mathisen J, Ottersen OP, editors. Glutamate. Amersterdam: Elsevier Science.
[41]
Shigemoto R, Nomura S, Ohishi H, Sugihara H, Nakanishi S, et al. (1993) Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett 163: 53–57.
[42]
Sanon NT, Pelletier JG, Carmant L, Lacaille JC (2010) Interneuron subtype specific activation of mGluR1/5 during epileptiform activity in hippocampus. Epilepsia 51: 1607–1618.
[43]
Sun W, McConnell E, Pare JF, Xu Q, Chen M, et al. (2013) Glutamate-dependent neuroglial calcium signaling differs between young and adult brain. Science 339: 197–200.
[44]
Lopez-Bendito G, Shigemoto R, Fairen A, Lujan R (2002) Differential distribution of group I metabotropic glutamate receptors during rat cortical development. Cereb Cortex 12: 625–638.
[45]
van Hooft JA, Giuffrida R, Blatow M, Monyer H (2000) Differential expression of group I metabotropic glutamate receptors in functionally distinct hippocampal interneurons. J Neurosci 20: 3544–3551.
[46]
Sun QQ, Zhang Z, Jiao Y, Zhang C, Szabo G, et al. (2009) Differential metabotropic glutamate receptor expression and modulation in two neocortical inhibitory networks. J Neurophysiol 101: 2679–2692.
[47]
Ballester-Rosado CJ, Albright MJ, Wu CS, Liao CC, Zhu J, et al. (2010) mGluR5 in cortical excitatory neurons exerts both cell-autonomous and -nonautonomous influences on cortical somatosensory circuit formation. J Neurosci 30: 16896–16909.
[48]
Xu J, Zhu Y, Contractor A, Heinemann SF (2009) mGluR5 has a critical role in inhibitory learning. J Neurosci 29: 3676–3684.
[49]
Goebbels S, Bormuth I, Bode U, Hermanson O, Schwab MH, et al. (2006) Genetic targeting of principal neurons in neocortex and hippocampus of NEX-Cre mice. Genesis 44: 611–621.
[50]
Bouwknecht JA, Paylor R (2002) Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res 136: 489–501.
[51]
Bouwknecht JA, van der Gugten J, Groenink L, Olivier B, Paylor RE (2004) Behavioral and physiological mouse models for anxiety: effects of flesinoxan in 129S6/SvEvTac and C57BL/6J mice. Eur J Pharmacol 494: 45–53.
[52]
Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49: 1053–1066.
[53]
Thomas AM, Bui N, Perkins JR, Yuva-Paylor LA, Paylor R (2011) Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome. Psychopharmacology (Berl).
[54]
Crawley JN, Paylor R (1997) A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm Behav 31: 197–211.
[55]
McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R (2001) The use of behavioral test batteries: effects of training history. Physiol Behav 73: 705–717.
[56]
Paylor R, Spencer CM, Yuva-Paylor LA, Pieke-Dahl S (2006) The use of behavioral test batteries, II: effect of test interval. Physiol Behav 87: 95–102.
[57]
Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, et al. (2006) Exaggerated behavioral phenotypes in Fmr1/Fxr2 double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. Hum Mol Genet 15: 1984–1994.
[58]
Spencer CM, Alekseyenko O, Hamilton SM, Thomas AM, Serysheva E, et al. (2011) Modifying behavioral phenotypes in Fmr1KO mice: genetic background differences reveal autistic-like responses. Autism Res 4: 40–56.
[59]
Wu CS, Chen H, Sun H, Zhu J, Jew CP, et al. (2013) GPR55, a G-Protein Coupled Receptor for Lysophosphatidylinositol, Plays a Role in Motor Coordination. PLoS ONE 8: e60314.
[60]
Paylor R, Crawley JN (1997) Inbred strain differences in prepulse inhibition of the mouse startle response. Psychopharmacology (Berl) 132: 169–180.
[61]
Moretti P, Bouwknecht JA, Teague R, Paylor R, Zoghbi HY (2005) Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome. Hum Mol Genet 14: 205–220.
[62]
Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, et al. (1998) Alpha7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem 5: 302–316.
[63]
Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, et al. (2009) Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 204: 361–373.
[64]
Chao HT, Chen H, Samaco RC, Xue M, Chahrour M, et al. (2010) Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468: 263–269.
[65]
Lafourcade M, Elezgarai I, Mato S, Bakiri Y, Grandes P, et al. (2007) Molecular components and functions of the endocannabinoid system in mouse prefrontal cortex. PLoS ONE 2: e709.
[66]
Tritto T, McCallum SE, Waddle SA, Hutton SR, Paylor R, et al. (2004) Null mutant analysis of responses to nicotine: deletion of beta2 nicotinic acetylcholine receptor subunit but not alpha7 subunit reduces sensitivity to nicotine-induced locomotor depression and hypothermia. Nicotine Tob Res 6: 145–158.
[67]
Peier AM, McIlwain KL, Kenneson A, Warren ST, Paylor R, et al. (2000) (Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features. Hum Mol Genet 9: 1145–1159.
[68]
Panenka WJ, Procyshyn RM, Lecomte T, Macewan GW, Flynn SW, et al.. (2012) Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug Alcohol Depend.
[69]
Greenhill LL (2001) Clinical effects of stimulant medication in ADHD. In: Solanto MV, Arnsten AFT, Castellanos FX, editors. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York: Oxford University Press. 31–71.
[70]
Crawley JN (2004) Designing mouse behavioral tasks relevant to autistic-like behaviors. Ment Retard Dev Disabil Res Rev 10: 248–258.
[71]
Monory K, Massa F, Egertova M, Eder M, Blaudzun H, et al. (2006) The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51: 455–466.
[72]
Adler L, Cohen J (2004) Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr Clin North Am 27: 187–201.
[73]
Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62: 617–627.
[74]
Nair J, Ehimare U, Beitman BD, Nair SS, Lavin A (2006) Clinical review: evidence-based diagnosis and treatment of ADHD in children. Mo Med 103: 617–621.
Durston S (2003) A review of the biological bases of ADHD: what have we learned from imaging studies? Ment Retard Dev Disabil Res Rev 9: 184–195.
[77]
Giedd JN, Blumenthal J, Molloy E, Castellanos FX (2001) Brain imaging of attention deficit/hyperactivity disorder. Ann N Y Acad Sci 931: 33–49.
[78]
Avale ME, Falzone TL, Gelman DM, Low MJ, Grandy DK, et al. (2004) The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/hyperactivity disorder. Mol Psychiatry 9: 718–726.
[79]
Zhu J, Zhang X, Xu Y, Spencer TJ, Biederman J, et al. (2012) Prenatal nicotine exposure mouse model showing hyperactivity, reduced cingulate cortex volume, reduced dopamine turnover, and responsiveness to oral methylphenidate treatment. J Neurosci 32: 9410–9418.
[80]
Volkow ND, Wang G, Fowler JS, Logan J, Gerasimov M, et al. (2001) Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21: RC121.
[81]
Shaltiel G, Maeng S, Malkesman O, Pearson B, Schloesser RJ, et al. (2008) Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry 13: 858–872.
[82]
Polter A, Beurel E, Yang S, Garner R, Song L, et al. (2010) Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 35: 1761–1774.
[83]
Eisener-Dorman AF, Bailey JS, Grabowski-Boase L, Huitron-Resendiz S, Roberts AJ, et al. (2013) Characterization of Highper, an ENU-induced mouse mutant with abnormal psychostimulant and stress responses. Psychopharmacology (Berl) 225: 407–419.
